Logo image of LNAI

LUNAI BIOWORKS INC (LNAI) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:LNAI - US29350E2037 - Common Stock

0.9709 USD
-0.02 (-1.53%)
Last: 12/26/2025, 8:00:00 PM
0.95 USD
-0.02 (-2.15%)
After Hours: 12/26/2025, 8:00:00 PM
Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to LNAI. LNAI was compared to 530 industry peers in the Biotechnology industry. LNAI has a bad profitability rating. Also its financial health evaluation is rather negative. LNAI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

LNAI had negative earnings in the past year.
LNAI had a negative operating cash flow in the past year.
LNAI had negative earnings in each of the past 5 years.
In the past 5 years LNAI always reported negative operating cash flow.
LNAI Yearly Net Income VS EBIT VS OCF VS FCFLNAI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M

1.2 Ratios

With a Return On Assets value of -1881.62%, LNAI is not doing good in the industry: 98.11% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -1881.62%
ROE N/A
ROIC N/A
ROA(3y)-761.62%
ROA(5y)-486.61%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LNAI Yearly ROA, ROE, ROICLNAI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 -500 -1K -1.5K -2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for LNAI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LNAI Yearly Profit, Operating, Gross MarginsLNAI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K -4K -5K

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, LNAI has more shares outstanding
The number of shares outstanding for LNAI has been increased compared to 5 years ago.
LNAI has a worse debt/assets ratio than last year.
LNAI Yearly Shares OutstandingLNAI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M
LNAI Yearly Total Debt VS Total AssetsLNAI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -111.94, we must say that LNAI is in the distress zone and has some risk of bankruptcy.
LNAI has a Altman-Z score of -111.94. This is amonst the worse of the industry: LNAI underperforms 96.04% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -111.94
ROIC/WACCN/A
WACCN/A
LNAI Yearly LT Debt VS Equity VS FCFLNAI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 0.04 indicates that LNAI may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.04, LNAI is doing worse than 97.74% of the companies in the same industry.
LNAI has a Quick Ratio of 0.04. This is a bad value and indicates that LNAI is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of LNAI (0.04) is worse than 97.55% of its industry peers.
Industry RankSector Rank
Current Ratio 0.04
Quick Ratio 0.04
LNAI Yearly Current Assets VS Current LiabilitesLNAI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for LNAI have decreased strongly by -72.28% in the last year.
EPS 1Y (TTM)-72.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%104.55%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LNAI Yearly Revenue VS EstimatesLNAI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 0 0 0 0 0

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LNAI. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LNAI Price Earnings VS Forward Price EarningsLNAI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LNAI Per share dataLNAI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -2 -4 -6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

LNAI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

LUNAI BIOWORKS INC

NASDAQ:LNAI (12/26/2025, 8:00:00 PM)

After market: 0.95 -0.02 (-2.15%)

0.9709

-0.02 (-1.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2025-11-14
Earnings (Next)02-17 2026-02-17
Inst Owners12.18%
Inst Owner ChangeN/A
Ins Owners7.99%
Ins Owner ChangeN/A
Market Cap22.75M
Revenue(TTM)N/A
Net Income(TTM)-130.97M
AnalystsN/A
Price TargetN/A
Short Float %13.66%
Short Ratio0.4
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-7.51
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.31
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS0
BVpS-0.56
TBVpS-0.81
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -1881.62%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-761.62%
ROA(5y)-486.61%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.04
Quick Ratio 0.04
Altman-Z -111.94
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-72.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%104.55%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y24.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y39.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.46%
OCF growth 3YN/A
OCF growth 5YN/A

LUNAI BIOWORKS INC / LNAI FAQ

What is the fundamental rating for LNAI stock?

ChartMill assigns a fundamental rating of 0 / 10 to LNAI.


Can you provide the valuation status for LUNAI BIOWORKS INC?

ChartMill assigns a valuation rating of 0 / 10 to LUNAI BIOWORKS INC (LNAI). This can be considered as Overvalued.


Can you provide the profitability details for LUNAI BIOWORKS INC?

LUNAI BIOWORKS INC (LNAI) has a profitability rating of 0 / 10.


How financially healthy is LUNAI BIOWORKS INC?

The financial health rating of LUNAI BIOWORKS INC (LNAI) is 0 / 10.